Product Description

Nivolumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody developed for therapeutic use.

How Nivolumab Works

Nivolumab is directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1/PCD-1). By targeting PD-1, nivolumab exhibits immune checkpoint inhibitory and antineoplastic activities.

What Does Nivolumab Do?

Nivolumab works to block PD-1, helping restore immune responses and promoting anti-tumor effects.

Who Makes Nivolumab?

Nivolumab is supplied by TargetMol.

Chemical Properties

References and Literature

1. Sundar R, et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85-96.2. Wang C, et al. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates. Cancer Immunology Research. 2014 Sep;2(9):846-56.